Clinical Trial Update: Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating adding chidamide to decitabine plus camrelizumab in patients with relapsed/refractory classical Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chidamide (chidamide)
• Decitabine (Decitabine)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN